Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaccitech Plc ADR (NQ: VACC )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 4.950 (1)
Ask (Size) 5.180 (5)
Prev. Close 5.000
Today's Range N/A - N/A
52wk Range 1.640 - 4.540
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga

Performance

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Analyst Expectations for Vaccitech's Future
Via Benzinga
Vaccitech: Q1 Earnings Insights
Via Benzinga
Vaccitech Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
Via FinancialNewsMedia
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
From Vaccitech plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
From Vaccitech plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
From Vaccitech plc
Via GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
From Arbutus Biopharma Corporation
Via GlobeNewswire
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
From Vaccitech plc
Via GlobeNewswire
Over $4M Bet On Diversified Healthcare Trust? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
From Vaccitech plc
Via GlobeNewswire
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Via InvestorPlace
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
From Vaccitech plc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.